Literature DB >> 26181453

Primary hepatic mucosa-associated lymphoid tissue (MALT) lymphoma.

Tetsuya Hamada1, Satoru Kakizaki2, Hiromi Koiso3, Hiroyuki Irisawa4, Sumihito Nobusawa5, Masatomo Mori6.   

Abstract

Primary hepatic mucosa-associated lymphoid tissue (MALT) lymphoma is extremely rare, and the etiology of disease is not fully understood. We present herein the case of a primary hepatic MALT lymphoma with Helicobacter pylori and hepatitis C virus infection. A 71-year-old male was admitted to our institution to undergo a precise evaluation of a hepatic tumor incidentally detected during a computed tomography (CT) scan for chest examination. Dynamic CT showed faint enhancement during the arterial phase. The gadoxetate disodium-enhanced magnetic resonance imaging showed a hyper-intensity on the arterial phase and low intensity during the late and hepatocyte phases. Liver biopsy specimen showed small to intermediate size atypical lymphocytes with positive CD20 immunohistochemical staining. It was finally diagnosed as primary hepatic MALT lymphoma. FDG-PET/CT showed faintly increased uptake with a maximum standardized uptake value of 4.6, and did not show other pathological uptake. We present the rare case of primary hepatic MALT lymphoma and discussed the etiology of this disease.

Entities:  

Keywords:  Helicobacter pylori; Hepatitis C virus; Liver neoplasms; Lymphoma

Year:  2013        PMID: 26181453     DOI: 10.1007/s12328-013-0362-5

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  21 in total

1.  Hepatic mucosa-associated lymphoid tissue (MALT) lymphoma associated with hepatitis C.

Authors:  Shugo Mizuno; Shuji Isaji; Masami Tabata; Shinji Uemoto; Hiroshi Imai; Katsuya Shiraki
Journal:  J Hepatol       Date:  2002-12       Impact factor: 25.083

2.  Helicobacter pylori and the risk of benign and malignant biliary tract disease.

Authors:  Milutin Bulajic; Patrick Maisonneuve; Wulf Schneider-Brachert; Petra Müller; Udo Reischl; Bojan Stimec; Norbert Lehn; Albert B Lowenfels; Matthias Löhr
Journal:  Cancer       Date:  2002-11-01       Impact factor: 6.860

3.  Occurrence and prognosis of extranodal lymphomas.

Authors:  C Freeman; J W Berg; S J Cutler
Journal:  Cancer       Date:  1972-01       Impact factor: 6.860

4.  High relapse rate in patients with MALT lymphoma warrants lifelong follow-up.

Authors:  Markus Raderer; Berthold Streubel; Stefan Woehrer; Andreas Puespoek; Ulrich Jaeger; Michael Formanek; Andreas Chott
Journal:  Clin Cancer Res       Date:  2005-05-01       Impact factor: 12.531

5.  Primary hepatic B-cell lymphoma of mucosa-associated lymphoid tissue.

Authors:  C M Kirk; D Lewin; J Lazarchick
Journal:  Arch Pathol Lab Med       Date:  1999-08       Impact factor: 5.534

6.  Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.

Authors:  Emanuele Zucca; Annarita Conconi; Ennio Pedrinis; Sergio Cortelazzo; Teresio Motta; Mary K Gospodarowicz; Bruce J Patterson; Andrés J M Ferreri; Maurilio Ponzoni; Liliana Devizzi; Roberto Giardini; Graziella Pinotti; Carlo Capella; Pier Luigi Zinzani; Stefano Pileri; Armando López-Guillermo; Elias Campo; Achille Ambrosetti; Luca Baldini; Franco Cavalli
Journal:  Blood       Date:  2002-11-27       Impact factor: 22.113

7.  Detection of Helicobacter species in the liver of patients with and without primary liver carcinoma.

Authors:  P Avenaud; A Marais; L Monteiro; B Le Bail; P Bioulac Sage; C Balabaud; F Mégraud
Journal:  Cancer       Date:  2000-10-01       Impact factor: 6.860

8.  Disappearance of gastric mucosa-associated lymphoid tissue in hepatitis C virus-positive patients after anti-hepatitis C virus therapy.

Authors:  Antonio Tursi; Giovanni Brandimarte; Monica Torello
Journal:  J Clin Gastroenterol       Date:  2004-04       Impact factor: 3.062

9.  Primary hepatic low-grade B-cell lymphoma of MALT-type associated with Helicobacter pylori infection.

Authors:  Takeshi Iida; Makoto Iwahashi; Masaki Nakamura; Mikihito Nakamori; Shozo Yokoyama; Masaji Tani; Hiroko Akamatsu; Hirokazu Nakamine; Hiroki Yamaue
Journal:  Hepatogastroenterology       Date:  2007-09

10.  Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma.

Authors:  Markus Raderer; Gerald Jäger; Stefan Brugger; Andreas Püspök; Wolfgang Fiebiger; Johannes Drach; Andrew Wotherspoon; Andreas Chott
Journal:  Oncology       Date:  2003       Impact factor: 2.935

View more
  5 in total

1.  A case of primary hepatic extranodal marginal zone B-cell mucosa-associated lymphoid tissue (MALT) lymphoma treated by radiofrequency ablation (RFA), and a literature review.

Authors:  Zhe Xu; Chong Pang; Jidong Sui; Zhenming Gao
Journal:  J Int Med Res       Date:  2021-03       Impact factor: 1.671

2.  CT, MRI, and 18F-FDG PET/CT Findings in Untreated Pulmonary and Hepatic B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) Over a Five-Year Period: A Case Report.

Authors:  Aisheng Dong; Zhengguang Xiao; Jianmin Yang; Changjing Zuo
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

Review 3.  Primary hepatic extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type: A case report and literature review.

Authors:  Shuilin Dong; Lin Chen; Yifa Chen; Xiaoping Chen
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

Review 4.  Primary hepatic mucosa-associated lymphoid tissue lymphoma: A case report and literature review.

Authors:  Huazhi Xie; Jian Lv; Yong Ji; Xinjian Du; Xin Yang
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

5.  Primary Hepatic Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in a Patient with Chronic Hepatitis B Virus Infection: Case Report and Summary of the Literature.

Authors:  Yuki Yamashita; Satoru Joshita; Hiroyuki Kobayashi; Shun-Ichi Wakabayashi; Ayumi Sugiura; Tomoo Yamazaki; Takeji Umemura
Journal:  Medicina (Kaunas)       Date:  2021-03-18       Impact factor: 2.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.